Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

There is disclosed a compound, a pharmaceutical composition and a method of cancer treatment with an improved Myc inhibitor compound. More specifically, there is disclosed an improved compound having with improved solubility, improved binding characteristics and better efficacy and therapeutic activity inhibiting c-MYC wherein the improved compound comprises a tri-substituted pyridine having a thiazoyl moiety at position R.sup.1 versus an earlier disclosed genus of tri-substituted pyridine structures.

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Provided is a compound of Chemical Formula 1:

##STR00001##

wherein, in Chemical Formula 1: X.sub.1 to X.sub.3 are each independently N or CH, provided that at least one of X.sub.1 to X.sub.3 is N; X.sub.4 to X.sub.6 are each independently N or CH, provided that at least one of X.sub.4 to X.sub.6 is N; Ar.sub.1 to Ar.sub.4 are each independently a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing any one or more selected from the group consisting of N, O, and S; L.sub.1 to L.sub.3 are each independently a single bond, a substituted or unsubstituted C.sub.6-60 arylene, or a substituted or unsubstituted C.sub.2-60 heteroarylene containing any one or more selected from the group consisting of N, O, and S; and n is 1 or 2,
and an organic light emitting device including the same.

Provided is a compound of Chemical Formula 1:

##STR00001##

wherein, in Chemical Formula 1: X.sub.1 to X.sub.3 are each independently N or CH, provided that at least one of X.sub.1 to X.sub.3 is N; X.sub.4 to X.sub.6 are each independently N or CH, provided that at least one of X.sub.4 to X.sub.6 is N; Ar.sub.1 to Ar.sub.4 are each independently a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing any one or more selected from the group consisting of N, O, and S; L.sub.1 to L.sub.3 are each independently a single bond, a substituted or unsubstituted C.sub.6-60 arylene, or a substituted or unsubstituted C.sub.2-60 heteroarylene containing any one or more selected from the group consisting of N, O, and S; and n is 1 or 2,
and an organic light emitting device including the same.

The present subject matter relates to compounds that have aggregation-induced emission (AIE) characteristics and are capable of generating Raman signals in the Raman cell-silent region (1800 cm.sup.−1-2800 cm.sup.−1). The compounds can be used in dual-mode cell imaging by fluorescence and Raman microscopes